ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options Ann Hematol
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma-final results of a phase I/IIa study Haematologica
Improving the EASIX' predictive power for NRM in adults undergoing allogeneic hematopoietic cell transplantation BONE MARROW TRANSPL
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022 EClinicalMedicine
Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues Hum Genomics
Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients BBA-MOL CELL RES
T-TAS(®) 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion BLOOD TRANSFUS-ITALY
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis Hemasphere
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms Mol Cancer Ther
A robust and validated integrated prognostic index for defining risk groups in adult ALL: A EWALL collaborative study Blood Adv